# Alphatec Holdings, Inc.: financial statements, quarterly

ATEC · Nasdaq · CIK 1350653 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atec.md) · [Financials](/companies/atec/financials.md) · [Filings](/companies/atec/filings.md) · [Insiders](/companies/atec/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atec/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [118](/filings/0000950170-24-119083.md) | [138 d](/filings/0001193125-26-067393.md) | [138](/filings/0000950170-25-061974.md) | [146](/filings/0000950170-25-100963.md) | [151](/filings/0001193125-25-258790.md) | [177 d](/filings/0001193125-26-067393.md) | [169](/filings/0001193125-26-206683.md) | [186](/filings/0001193125-26-333051.md) | [197](/filings/0001193125-25-258790.md) | [213 d](/filings/0001193125-26-067393.md) | [192](/filings/0001193125-26-206683.md) | [214](/filings/0001193125-26-333051.md) |
| Cost of revenue | $m | [38.2](/filings/0000950170-24-119083.md) | [42.8 d](/filings/0001193125-26-067393.md) | [41.1](/filings/0000950170-25-061974.md) | [43.0](/filings/0000950170-25-100963.md) | [48.0](/filings/0001193125-25-258790.md) | [55.2 d](/filings/0001193125-26-067393.md) | [53.2](/filings/0001193125-26-206683.md) | [56.4](/filings/0001193125-26-333051.md) | [59.2](/filings/0001193125-25-258790.md) | [63.4 d](/filings/0001193125-26-067393.md) | [55.6](/filings/0001193125-26-206683.md) | [59.4](/filings/0001193125-26-333051.md) |
| Gross profit | $m | [80.0](/filings/0000950170-24-119083.md) | [95.2 d](/filings/0001193125-26-067393.md) | [97.4](/filings/0000950170-25-061974.md) | [103](/filings/0000950170-25-100963.md) | [103](/filings/0001193125-25-258790.md) | [122 d](/filings/0001193125-26-067393.md) | [116](/filings/0001193125-26-206683.md) | [129](/filings/0001193125-26-333051.md) | [137](/filings/0001193125-25-258790.md) | [149 d](/filings/0001193125-26-067393.md) | [136](/filings/0001193125-26-206683.md) | [154](/filings/0001193125-26-333051.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [91.4](/filings/0000950170-24-119083.md) | [104 d](/filings/0001193125-26-067393.md) | [114](/filings/0000950170-25-061974.md) | [113](/filings/0000950170-25-100963.md) | [109](/filings/0001193125-25-258790.md) | [115 d](/filings/0001193125-26-067393.md) | [127](/filings/0001193125-26-206683.md) | [119](/filings/0001193125-26-333051.md) | [124](/filings/0001193125-25-258790.md) | [129 d](/filings/0001193125-26-067393.md) | [137](/filings/0001193125-26-206683.md) | [134](/filings/0001193125-26-333051.md) |
| Operating income | $m | [(38.4)](/filings/0000950170-24-119083.md) | [(44.8) d](/filings/0001193125-26-067393.md) | [(43.3)](/filings/0000950170-25-061974.md) | [(35.3)](/filings/0000950170-25-100963.md) | [(33.7)](/filings/0001193125-25-258790.md) | [(23.8) d](/filings/0001193125-26-067393.md) | [(44.3)](/filings/0001193125-26-206683.md) | [(13.1)](/filings/0001193125-26-333051.md) | [(15.9)](/filings/0001193125-25-258790.md) | [(8.8) d](/filings/0001193125-26-067393.md) | [(22.6)](/filings/0001193125-26-206683.md) | [(1.9)](/filings/0001193125-26-333051.md) |
| Interest expense | $m | [4.5](/filings/0000950170-24-119083.md) | [4.4 d](/filings/0001193125-26-067393.md) | [5.3](/filings/0000950170-25-061974.md) | [5.8](/filings/0000950170-25-100963.md) | [6.6](/filings/0001193125-25-258790.md) | [7.2 d](/filings/0001193125-26-067393.md) | [7.8](/filings/0001193125-26-206683.md) | [12.3](/filings/0001193125-26-333051.md) | [12.9](/filings/0001193125-25-258790.md) | [12.9 d](/filings/0001193125-26-067393.md) | [11.7](/filings/0001193125-26-206683.md) | [11.0](/filings/0001193125-26-333051.md) |
| Income tax | $m | [(0.1)](/filings/0000950170-24-119083.md) | [(0.1) d](/filings/0001193125-26-067393.md) | [(0.1)](/filings/0000950170-25-061974.md) | [(0.3)](/filings/0000950170-25-100963.md) | [(0.0)](/filings/0001193125-25-258790.md) | [0.4 d](/filings/0001193125-26-067393.md) | [(0.1)](/filings/0001193125-26-206683.md) | [(0.0)](/filings/0001193125-26-333051.md) | [0.1](/filings/0001193125-25-258790.md) | [(0.0) d](/filings/0001193125-26-067393.md) | [0.1](/filings/0001193125-26-206683.md) | [0.2](/filings/0001193125-26-333051.md) |
| Net income | $m | [(42.7)](/filings/0000950170-24-119083.md) | [(49.1) d](/filings/0001193125-26-067393.md) | [(48.5)](/filings/0001193125-25-258790.md) | [(40.7)](/filings/0001193125-25-258790.md) | [(39.6)](/filings/0001193125-25-258790.md) | [(33.3) d](/filings/0001193125-26-067393.md) | [(51.9)](/filings/0001193125-26-333051.md) | [(41.1)](/filings/0001193125-26-333051.md) | [(28.6)](/filings/0001193125-25-258790.md) | [(21.7) d](/filings/0001193125-26-067393.md) | [(33.9)](/filings/0001193125-26-333051.md) | [(25.8)](/filings/0001193125-26-333051.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0000950170-24-119083.md) | not reported | [(0.34)](/filings/0000950170-25-061974.md) | [(0.29)](/filings/0000950170-25-100963.md) | [(0.28)](/filings/0001193125-25-258790.md) | not reported | [(0.35)](/filings/0001193125-26-206683.md) | [(0.27)](/filings/0001193125-26-333051.md) | [(0.19)](/filings/0001193125-25-258790.md) | not reported | [(0.22)](/filings/0001193125-26-206683.md) | [(0.16)](/filings/0001193125-26-333051.md) |
| Basic EPS | $ per share | [(0.35)](/filings/0000950170-24-119083.md) | not reported | [(0.34)](/filings/0000950170-25-061974.md) | [(0.29)](/filings/0000950170-25-100963.md) | [(0.28)](/filings/0001193125-25-258790.md) | not reported | [(0.35)](/filings/0001193125-26-206683.md) | [(0.27)](/filings/0001193125-26-333051.md) | [(0.19)](/filings/0001193125-25-258790.md) | not reported | [(0.22)](/filings/0001193125-26-206683.md) | [(0.16)](/filings/0001193125-26-333051.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [123](/filings/0000950170-23-059489.md) | [221](/filings/0000950170-25-027916.md) | [144](/filings/0000950170-24-054691.md) | [99.8](/filings/0000950170-24-088670.md) | [81.0](/filings/0000950170-24-119083.md) | [139](/filings/0001193125-26-067393.md) | [153](/filings/0000950170-25-061974.md) | [157](/filings/0000950170-25-100963.md) | [156](/filings/0001193125-25-258790.md) | [161](/filings/0001193125-26-333051.md) | [140](/filings/0001193125-26-206683.md) | [119](/filings/0001193125-26-333051.md) |
| Current assets | $m | [334](/filings/0000950170-23-059489.md) | [451](/filings/0000950170-25-027916.md) | [405](/filings/0000950170-24-054691.md) | [377](/filings/0000950170-24-088670.md) | [362](/filings/0000950170-24-119083.md) | [417](/filings/0001193125-26-067393.md) | [435](/filings/0000950170-25-061974.md) | [443](/filings/0000950170-25-100963.md) | [440](/filings/0001193125-25-258790.md) | [451](/filings/0001193125-26-333051.md) | [456](/filings/0001193125-26-206683.md) | [449](/filings/0001193125-26-333051.md) |
| Total assets | $m | [670](/filings/0000950170-23-059489.md) | [805](/filings/0000950170-25-027916.md) | [775](/filings/0000950170-24-054691.md) | [769](/filings/0000950170-24-088670.md) | [746](/filings/0000950170-24-119083.md) | [776](/filings/0001193125-26-067393.md) | [785](/filings/0000950170-25-061974.md) | [790](/filings/0000950170-25-100963.md) | [787](/filings/0001193125-25-258790.md) | [791](/filings/0001193125-26-333051.md) | [799](/filings/0001193125-26-206683.md) | [791](/filings/0001193125-26-333051.md) |
| Current liabilities | $m | [148](/filings/0000950170-23-059489.md) | [158](/filings/0000950170-25-027916.md) | [169](/filings/0000950170-24-054691.md) | [169](/filings/0000950170-24-088670.md) | [156](/filings/0000950170-24-119083.md) | [153](/filings/0001193125-26-067393.md) | [158](/filings/0000950170-25-061974.md) | [154](/filings/0000950170-25-100963.md) | [221](/filings/0001193125-25-258790.md) | [219](/filings/0001193125-26-333051.md) | [240](/filings/0001193125-26-206683.md) | [238](/filings/0001193125-26-333051.md) |
| Long-term debt | $m | [507](/filings/0000950170-23-059489.md) | [511](/filings/0000950170-25-027916.md) | [512](/filings/0000950170-24-054691.md) | [517](/filings/0000950170-24-088670.md) | [526](/filings/0000950170-24-119083.md) | [575](/filings/0001193125-26-067393.md) | [546](/filings/0000950170-25-061974.md) | [552](/filings/0000950170-25-100963.md) | [495](/filings/0001193125-25-258790.md) | [501](/filings/0001193125-26-333051.md) | [508](/filings/0001193125-26-206683.md) | [511](/filings/0001193125-26-333051.md) |
| Current portion of debt | $m | [1.8](/filings/0000950170-23-059489.md) | [1.8](/filings/0000950170-25-027916.md) | [2.5](/filings/0000950170-24-054691.md) | [2.3](/filings/0000950170-24-088670.md) | [1.8](/filings/0000950170-24-119083.md) | [1.7](/filings/0001193125-26-067393.md) | [2.6](/filings/0000950170-25-061974.md) | [1.9](/filings/0000950170-25-100963.md) | [64.7](/filings/0001193125-25-258790.md) | [64.5](/filings/0001193125-26-067393.md) | [65.5](/filings/0001193125-26-206683.md) | [65.0](/filings/0001193125-26-333051.md) |
| Short-term borrowings | $m | [1.8](/filings/0000950170-23-059489.md) | [1.8](/filings/0000950170-25-027916.md) | [2.5](/filings/0000950170-24-054691.md) | [2.3](/filings/0000950170-24-088670.md) | [1.8](/filings/0000950170-24-119083.md) | [1.7](/filings/0001193125-26-067393.md) | [2.6](/filings/0000950170-25-061974.md) | [1.9](/filings/0000950170-25-100963.md) | [64.7](/filings/0001193125-25-258790.md) | [64.5](/filings/0001193125-26-333051.md) | [65.5](/filings/0001193125-26-206683.md) | [65.0](/filings/0001193125-26-333051.md) |
| Shareholders' equity | $m | [(44.2)](/filings/0000950170-24-119083.md) | [78.1](/filings/0001193125-26-067393.md) | [37.6](/filings/0001193125-25-258790.md) | [17.1](/filings/0001193125-25-258790.md) | [(1.4)](/filings/0001193125-25-258790.md) | [(14.2)](/filings/0001193125-26-333051.md) | [(85.9)](/filings/0001193125-26-333051.md) | [23.8](/filings/0001193125-26-333051.md) | [11.5](/filings/0001193125-25-258790.md) | [12.4](/filings/0001193125-26-333051.md) | [(5.3)](/filings/0001193125-26-333051.md) | [(12.1)](/filings/0001193125-26-333051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.3) d](/filings/0000950170-24-119083.md) | [(25.0) d](/filings/0001193125-26-067393.md) | [(38.4)](/filings/0000950170-25-061974.md) | [(11.4) d](/filings/0000950170-25-100963.md) | [(5.3) d](/filings/0001193125-25-258790.md) | [10.5 d](/filings/0001193125-26-067393.md) | [(5.0)](/filings/0001193125-26-206683.md) | [15.5 d](/filings/0001193125-26-333051.md) | [14.0 d](/filings/0001193125-25-258790.md) | [20.7 d](/filings/0001193125-26-067393.md) | [1.3](/filings/0001193125-26-206683.md) | [20.5 d](/filings/0001193125-26-333051.md) |
| Capital expenditure | $m | [19.4 d](/filings/0000950170-24-119083.md) | [25.7 d](/filings/0001193125-26-067393.md) | [31.3](/filings/0000950170-25-061974.md) | [34.1 d](/filings/0000950170-25-100963.md) | [15.8 d](/filings/0001193125-25-258790.md) | [2.0 d](/filings/0001193125-26-067393.md) | [9.9](/filings/0001193125-26-206683.md) | [10.3 d](/filings/0001193125-26-333051.md) | [9.2 d](/filings/0001193125-25-258790.md) | [13.0 d](/filings/0001193125-26-067393.md) | [12.1](/filings/0001193125-26-206683.md) | [19.9 d](/filings/0001193125-26-333051.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [105](/filings/0000950170-23-059489.md) | [110](/filings/0000950170-24-054691.md) | [119](/filings/0000950170-24-088670.md) | [122](/filings/0000950170-24-119083.md) | [141](/filings/0000950170-25-061974.md) | [143](/filings/0000950170-25-100963.md) | [143](/filings/0001193125-25-258790.md) | [147](/filings/0001193125-26-206683.md) | [150](/filings/0001193125-26-333051.md) | [151](/filings/0001193125-25-258790.md) | [154](/filings/0001193125-26-206683.md) | [157](/filings/0001193125-26-333051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 154,451,076 at 2026-07-28, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-333051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.